Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B cells, which has established benefit in RA both with regards to clinical efficacy and ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

Leiden Professor of Translational Rheumatology Hans Ulrich Scherer has one foot in the clinic, where he helps patients, and ...

July 22, 2024 — Scientists have discovered a way to turn the body's B cells into tiny surveillance machines and antibody factories that can pump out specially designed antibodies to destroy ...

Scientists have identified human antibodies capable of targeting the proteins responsible for severe malaria, potentially paving the way for new vaccines or treatments. Using organ-on-a-chip ...